2021
DOI: 10.1007/978-981-33-6044-0_7
|View full text |Cite
|
Sign up to set email alerts
|

Challenges and Strategies for Current Classifications of Depressive Disorders: Proposal for Future Diagnostic Standards

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
2

Relationship

2
8

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 71 publications
0
5
0
1
Order By: Relevance
“…There are many possible symptom combinations displayed by patients with MDD (Park and Kim, 2021). At the core of the disorder, there are depressed mood and anhedonia.…”
Section: Heritability Etiology and Environment In Disorders Associate...mentioning
confidence: 99%
“…There are many possible symptom combinations displayed by patients with MDD (Park and Kim, 2021). At the core of the disorder, there are depressed mood and anhedonia.…”
Section: Heritability Etiology and Environment In Disorders Associate...mentioning
confidence: 99%
“…A temática gerou controvérsias 11,12 durante a elaboração da última revisão do Manual Diagnóstico e Estatístico de Transtornos Mentais (DSM-5), considerando propostas que reduziriam o limiar diagnóstico de transtornos depressivos ao remover o luto recente como critério de exclusão 13 . Além de tanger questões filosóficas e científicas, a patologização das respostas emocionais frente à perda poderia representar -adicionalmente aos dilemas éticos importantes 14,15 -uma oportunidade para alavancar a prescrição dos psicofármacos e promover intervenções farmacológicas -a "farmaceuticalização" aplicada ao cotidiano, seja ela intercedida por profissionais da saúde ou não, via automedicação 16,17 .…”
Section: Patologização Do Sofrimento E O Aumento No Consumo De Psicofármacosunclassified
“…Major depressive disorder (MDD) is generally considered a heterogeneous disease,1 with significant variability in symptom patterns, course trajectories and treatment responses 2. Therefore, studying subgroups or subtypes of patients with MDD that were more homogenous could help reduce research heterogeneity, better identify aetiological mechanisms, and develop more patient-specific diagnostic and therapeutic biomarkers.…”
Section: Introductionmentioning
confidence: 99%